# PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

> **NCT04745949** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 31 (estimated)

## Conditions studied

- Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Prednisone
- **OTHER:** Quality-of-Life Assessment
- **BIOLOGICAL:** Rituximab

## Key facts

- **NCT ID:** NCT04745949
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-10
- **Primary completion:** 2027-08-03
- **Final completion:** 2027-08-03
- **Target enrollment:** 31 (ESTIMATED)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04745949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04745949, "PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04745949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*